Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Lipari Mining and SpurChain Partner to Tokenize Natural Diamond Production (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Recent & Breaking News (NDAQ:PLUR)

Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico

GlobeNewswire October 8, 2025

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

GlobeNewswire May 15, 2025

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

GlobeNewswire April 28, 2025

Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel

GlobeNewswire April 10, 2025

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

GlobeNewswire March 5, 2025

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

GlobeNewswire February 19, 2025

Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million

GlobeNewswire February 4, 2025

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

GlobeNewswire January 23, 2025

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

GlobeNewswire December 19, 2024

Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025

GlobeNewswire December 9, 2024

Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns

GlobeNewswire November 25, 2024

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

ACCESS Newswire November 12, 2024

Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority

GlobeNewswire October 28, 2024

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

GlobeNewswire July 18, 2024

Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply

GlobeNewswire July 8, 2024

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

GlobeNewswire June 18, 2024

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

GlobeNewswire June 6, 2024

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

GlobeNewswire May 20, 2024

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

GlobeNewswire May 2, 2024

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

GlobeNewswire April 8, 2024